CONSHOHOCKEN, Pa. ( TheStreet) -- U.S. regulators rejected NuPathe's ( PATH) migraine patch Zelrix, the company said Tuesday.

NuPathe shares were down 51% to $1.99 in pre-market trading.

NuPathe's Zelrix is a patch that uses electric current (via a small battery and chip) to actively push the commonly used migraine medicine sumatriptan through the skin and into the patient's bloodstream.

The U.S. Food and Drug Administration rejected Zelrix, citing lingering questions and concerns about manufacturing and safety, NuPathe said, adding that additional studies may be conducted to address the issues raised by FDA.

NuPathe plans to meet with FDA to discuss ways it can address FDA's concerns, but the company offered no timeline, only saying that Zelrix will not be launched in the first half of 2012, as previously expected.

NuPathe shares were halted Monday afternoon at $4.05 a share. The company had $36 million, or $2.46 a share, in cash at the end of the second quarter.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Teva (TEVA) Acquires NuPathe (PATH) for $144 Million

NuPathe Picks Teva as Merger Partner

Why NuPathe Inc. (PATH) Is Up Today

Nupathe's Failure to Launch Leads to Modest Takeover

5 Stocks Under $10 Set to Soar